Alopexx Oncology, LLC (Alopexx)

Oncology Corporate Profile

HQ Location

100 Main Street, Suite 110
Concord, MA 1742

Company Description

Alopexx Oncology, LLC, a portfolio company of Alopexx Enterprises, licensed the rights to develop and commercialize its lead drug candidate DI- Leu16-IL2 from Provenance Biopharmaceuticals Corp. in 2011. Alopexx Enterprises consists of experts who have deep industry knowledge and technical expertise in all areas of drug development including, pharmacology, CMC, toxicology, medical and clinical operations, quality and regulatory affairs. Alopexx forms collaborations with academic institutions, biotech and pharmaceutical companies to advance its portfolio to deliver breakthrough therapies to patients in need.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
DI- Leu16-IL2immunocytokineNon-Hodgkin's Lymphoma (NHL)II

View additional information on product candidates here »


Recent News Headlines

There are no news items to display